Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390182 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2669593 | 0.85 | TSHR (0.43) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30749766 | 0.85 | TSHR (0.43) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29987444 | 0.83 | TSHR (0.42) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30197179 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL57316 | 0.80 | TSHR (0.48) | ALDH1A1MAPTTSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL29467181 | 0.80 | TSHR (0.48) | ALDH1A1MAPTTSHRSMN1; SMN2CYP3A4 | |
| SCHEMBL843761 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3085354 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15881241 | 0.78 | SMN1; SMN2 (0.41) | ALDH1A1MAPTTSHRSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 996 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557886-B | Synthesis method of 3-nitroisonicotinic acid methyl ester | 山西永津集团有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-116574455-A | High-temperature-resistant flexible polyimide anti-counterfeiting label material and preparation method thereof | 安徽融优新材料科技有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-115557886-A | Synthetic method of 3-nitroisonicotinic acid methyl ester | 山西永津集团有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-105541703-A | Triamine monomer containing pyridine structure and preparation method thereof | UNIV JILIN | 2016-05-04 | — | — | CN | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4725493-A2 | POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF | Shenzhen Keye Life Technologies, Co., Ltd. (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12559506-B2 | Indazole based compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-0379314-B1 | 3-(1,2,5,6-Tetrahydropyridyl)-pyrrolopyridines | PFIZER (US) | 1994-03-23 | — | — | EP | disclosed |
| US-5169947-A | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines | PFIZER INC. (US) | 1992-12-08 | — | — | US | disclosed |
| US-5051412-A | Pharmaceutically active 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines | PFIZER INC. (US) | 1991-09-24 | — | — | US | disclosed |
| EP-0429987-A2 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| CN-1044465-A | 3-(1,2,5, the 6-tetrahydro pyridyl)-pyrrolopyridine | PFIZER (US) | 1990-08-08 | — | — | CN | disclosed |
| WO-1990007926-A1 | 3-(1,2,5,6-TETRAHYDROPYRIDYL)-PYRROLOPYRIDINES | PFIZER INC. (US) | 1990-07-26 | — | — | WO | disclosed |
| EP-0379314-A1 | 3-(1,2,5,6-Tetrahydropyridyl)-pyrrolopyridines | PFIZER INC. (US) | 1990-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | ALDH1A1 3829/4885MAPT 3909/4885CYP1A2 4348/4885 |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | ALDH1A1 821/4885MAPT 3905/4885CYP1A2 2795/4885 |
| US-12559506-B2 | Indazole based compounds and associated methods of use | LRRK2, CRBN, CLK2 | ALDH1A1 3579/4885MAPT 187/4885CYP1A2 2912/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | ALDH1A1 877/4885MAPT 4832/4885CYP1A2 1705/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | ALDH1A1 3225/4885MAPT 250/4885CYP1A2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.